Literature DB >> 574979

The effect of doxorubicin on hepatic and cardiac glutathione.

J H Doroshow, G Y Locker, J Baldinger, C E Myers.   

Abstract

The effect of the antitumor antibiotic doxorubicin on glutathione and glutathione disulfide levels in mouse heart and liver has been evaluated. The glutathione content of hepatic and cardiac tissue from saline-treated controls exhibited a statistically significant diurnal variation. Doxorubicin administration produced a dose-related decrease in hepatic glutathione which was not blocked by pretreatment with the free radical scavenger alpha-tocopherol; a lesser drop in cardiac glutathione was also documented. These changes may play an important role in the metabolism and toxicity of doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 574979

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  22 in total

1.  Indication of reduced doxorubicin-induced cardiac toxicity by additional treatment with antioxidative substances.

Authors:  R Lenzhofer; D Magometschnigg; R Dudczak; C Cerni; C Bolebruch; K Moser
Journal:  Experientia       Date:  1983-01-15

Review 2.  Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.

Authors:  M Links; C Lewis
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

3.  P-gp Inhibition and Mitochondrial Impairment by Dual-Functional Nanostructure Based on Vitamin E Derivatives To Overcome Multidrug Resistance.

Authors:  Ruslan G Tuguntaev; Shizhu Chen; Ahmed Shaker Eltahan; Anbu Mozhi; Shubin Jin; Jinchao Zhang; Chan Li; Paul C Wang; Xing-Jie Liang
Journal:  ACS Appl Mater Interfaces       Date:  2017-05-10       Impact factor: 9.229

Review 4.  Doxorubicin cardiomyopathy.

Authors:  Kanu Chatterjee; Jianqing Zhang; Norman Honbo; Joel S Karliner
Journal:  Cardiology       Date:  2009-12-11       Impact factor: 1.869

5.  The effect of chronic adriamycin treatment on heart kidney and liver tissue of male and female rat.

Authors:  R H Julicher; L Sterrenberg; G R Haenen; A Bast; J Noordhoek
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

Review 6.  Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 7.  The role of active metabolites in drug toxicity.

Authors:  M Pirmohamed; N R Kitteringham; B K Park
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

8.  Protective effect of tetrahydroxystilbene glucoside on cardiotoxicity induced by doxorubicin in vitro and in vivo.

Authors:  Shao-hui Zhang; Wen-quan Wang; Jia-ling Wang
Journal:  Acta Pharmacol Sin       Date:  2009-11       Impact factor: 6.150

9.  Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine.

Authors:  J H Doroshow; G Y Locker; I Ifrim; C E Myers
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

10.  Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione.

Authors:  F Villani; M Galimberti; F Zunino; E Monti; A Rozza; E Lanza; L Favalli; P Poggi
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.